<DOC>
	<DOCNO>NCT01711567</DOCNO>
	<brief_summary>Entecavir , potent antiviral agent , widely use treatment-naïve chronic hepatitis B patient . However , 20 % patient show partial virologic response 2 year entecavir therapy ( 33 % HBeAg positive , 10 % HBeAg negative patient ) . Tenofovir nucleotide analogue potent antiviral activity . In addition , cross resistance two drug . Therefore assumed tenofovir would effective treatment chronic hepatitis B patient show partial virologic response ( detectable HBV DNA real time PCR 12 month treatment ) despite treatment entecavir . In study , compare efficacy switch tenofovir continue entecavir patient show partial virologic response entecavir .</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate vs. Entecavir Chronic Hepatitis B Patients With Partial Virologic Response Entecavir</brief_title>
	<detailed_description>The number patient need calculated use PASS 2008 . We hypothesize two-thirds ( 65 % ) patient receive TDF , one-fifth ( 20 % ) patient receive ETV , would achieve virologic response . We also assume 15 % drop-out rate ; thus , 22 patient need group achieve 80 % power demonstrate difference group 5 % level significance . The primary efficacy end point analyze per-protocol basis , include patient complete treatment schedule study . In contrast , intention-to-treat analysis include randomize subject , even dropped-out study 12 month , case treatment failure .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . CHB patient ( positive HBsAg 6 month ) 2 . Age 19 year old 3 . HBeAg positive negative patient 4 . Patients receive entecavir 0.5 mg 12 month 5 . Detectable HBV DNA real time PCR ( HBV &gt; 60 IU/mL ) 6 . Compensated liver function ( ChildPughTurcotte score ≤7 , prothrombin time 3 sec ULN INR ≤1.5 , serum albumin &gt; 3 g/dL , total bilirubin &lt; 2.5 mg/dL , history variceal bleeding , diuretic ascites require paracentesis , hepatic encephalopathy ) 1 . History treatment nucleotide analogue 0.5 mg ETV 2 . Serum creatinine level &gt; 1.5 mg/dL creatinine clearance &lt; 50 mL/min 3 . Absolute neutrophil count ≤ 1000 cell/mL 4 . Hemoglobin level ≤ 10 g/dL men ≤ 9 g/dL woman 5 . Antiviral resistance mutation rtT184 , rtS202 , rtM250 + rtM204V/I 6 . A positive antibody test human immunodeficiency virus , hepatitis C virus , hepatitis D virus 7 . Pregnancy lactation 8 . HCC ( case alfafetoprotein level 100 ng/mL , abdominal compute tomography magnetic resonance image perform exclude HCC ) 9 . Untreated malignancy HCC .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>TENOFOVIR</keyword>
	<keyword>ENTECAVIR</keyword>
	<keyword>PARTIAL RESPONDER</keyword>
</DOC>